Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EPO: renoprotection beyond anemia correction.

Danilo Fliser1, Ferdinand H Bahlmann, Hermann Haller

  • 1Division of Nephrology, Department of Internal Medicine, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. fliser.danilo@mh-hannover.de

Pediatric Nephrology (Berlin, Germany)
|September 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenicity and reactogenicity of the adjuvanted respiratory syncytial virus vaccine in patients with chronic kidney disease.

Clinical kidney journal·2026
Same author

Positive net antiviral benefit of bexarotene against patient-derived archetype and rearranged BK polyomavirus isolates.

Antiviral research·2026
Same author

The Role of Cytomegalovirus-specific Immunoglobulins as Modulators of Antigen-specific T-cell Expansion In Vitro.

Transplantation direct·2025
Same author

Urinary Dickkopf-3 Predicts GFR Loss in the General Population.

Kidney international reports·2025
Same author

Dickkopf-3 (DKK3) and the Progression of Diabetic Kidney Disease in Primary Health Care.

Diabetes·2025
Same author

Cellular and humoral immunogenicity of respiratory syncytial virus vaccination in solid organ transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025

Erythropoietin (EPO) offers kidney protection beyond red blood cell production by activating Akt signaling, inhibiting apoptosis, and preventing tissue damage in kidney injury. Clinical strategies explore EPO for renoprotection independent of anemia correction.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Erythropoietin (EPO) traditionally recognized for erythropoiesis.
  • Emerging evidence highlights EPO's significant tissue-protective roles, particularly in renal ischemia.
  • EPO's renoprotective effects are mediated through intracellular signaling pathways.

Purpose of the Study:

  • To review the non-hematological, tissue-protective effects of recombinant human EPO (rHuEPO) in kidney injury models.
  • To discuss the molecular mechanisms underlying EPO's renoprotection, focusing on Akt signaling.
  • To explore potential clinical applications of rHuEPO for renoprotection unrelated to anemia.

Main Methods:

  • Review of experimental data on rHuEPO in acute and chronic kidney injury models.

Related Experiment Videos

  • Analysis of the intracellular signaling cascade involving Akt and Bad.
  • Examination of clinical studies and strategies for rHuEPO in renal protection.

    • Main Results:

    • EPO activation of Akt signaling inhibits the proapoptotic factor Bad.
    • This pathway leads to the inhibition of programmed cell death (apoptosis) in renal cells.
    • rHuEPO demonstrates renoprotective effects in various experimental kidney injury settings.

    Conclusions:

    • EPO possesses critical non-hematological functions in protecting kidney tissue from damage.
    • The Akt/Bad pathway is a key mediator of EPO's anti-apoptotic and renoprotective effects.
    • rHuEPO and related compounds represent promising therapeutic avenues for kidney protection, independent of anemia treatment.